Participants in the study will take lasmiditan as needed for their migraine attacks over a 12-month period. The study will monitor how well the medication is tolerated by the participants and will track any side effects that may occur. The study will also look at how many participants stop using the medication due to any adverse effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how lasmiditan works in treating migraines in children. This research aims to provide valuable insights into the long-term use of lasmiditan for managing migraines in pediatric patients.

Participants in the study will be randomly assigned to receive either atorvastatin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will compare the effects of two different doses of atorvastatin, 20 mg and 40 mg, to see if they can decrease the frequency of migraines. The trial will last for several weeks, during which participants will take the medication daily and report the number of migraine days they experience.

The purpose of this study is to confirm whether the positive effects of atorvastatin observed in smaller studies can be replicated in a larger group of people. By participating, individuals will help researchers understand if atorvastatin can be an effective preventative treatment for those suffering from episodic migraines. The study is designed to be thorough and will involve multiple centers to ensure a comprehensive evaluation of the medication’s effects.

The study medication will be given through intramuscular injections, meaning the medicine is injected directly into muscles. Participants will receive either Xeomin or placebo injections over a period of 6 months. The treatment involves multiple injection sessions, with the medication being administered at specific intervals throughout the study period.

During the trial, participants will need to keep track of their headaches and migraine days using a headache diary. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of other migraine medications. The researchers will also track any side effects that may occur during the treatment period. The total study duration for each participant will be approximately 36 weeks.

The main purpose of this research is to determine if Xeomin is more effective than placebo in reducing the number of monthly migraine days. The study involves different doses of the medication, with participants receiving either Xeomin or placebo injections. The treatment period lasts for 6 months, during which participants will receive multiple injections.

The medication being tested, Xeomin, is a purified form of botulinum toxin that is free from complexing proteins. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of acute migraine medications. Throughout the study, participants will need to keep track of their migraine episodes and any changes in their condition.

The study medication or placebo will be given as a single treatment cycle. Throughout the study, participants will need to track their headaches and migraine days using an electronic diary. The study will monitor various aspects of participants’ health, including any changes in their condition and how their body responds to the treatment. The total duration of participation for each person will be 36 weeks.

During the study, researchers will evaluate how the treatment affects the number of days participants experience migraines each month. They will also monitor the use of other migraine medications and assess whether the study medication helps reduce both the frequency and severity of headaches. Regular health checks will be performed to ensure participant safety throughout the study period.

The study has two main phases. During the first phase, which lasts 12 weeks, participants will be randomly assigned to receive either cabergoline at a dose of 0.5 mg once weekly, cabergoline at a dose of 1.0 mg once weekly, or placebo once weekly. Neither the participants nor the doctors will know which treatment each person is receiving during this phase. Throughout the study, participants will keep a daily electronic diary to record their headaches and any medications they take for migraine attacks. The study will measure changes in the number of migraine days, how severe the headaches are, how often acute medications are needed, and how migraine affects daily activities and quality of life.

After the first 12-week phase, there will be an additional open-label phase where all participants will know what treatment they are receiving. The study will also collect blood samples to measure various substances in the body and look at genetic factors that might affect how people respond to the treatment. Safety will be monitored throughout the study by tracking any unwanted effects that occur. The total treatment period for each participant can last up to 24 weeks.

The study examines whether taking rimegepant for 7 days during each menstrual cycle can reduce the number of migraine days that women experience during their periods. The medication is given as a 75 mg dissolving tablet that is taken by mouth. Women participating in the study will receive either rimegepant or placebo during multiple menstrual cycles.

The treatment aims to decrease both the frequency and severity of menstrual migraine attacks. During the study, participants will need to track their migraine days, headache intensity, and use of other migraine medications. The study will monitor how the treatment affects participants’ daily activities and their ability to function during their menstrual periods.

The main purpose is to examine the long-term safety of eptinezumab in young patients aged 6 to 17 years who have either chronic migraine (frequent headaches occurring 15 or more days per month) or episodic migraine (less frequent headaches). The study will continue for 36 months, during which participants will receive the medication every 12 weeks.

During the study, doctors will monitor how the participants respond to the treatment by checking for any side effects and measuring the amount of medication in their blood. They will also assess how the treatment affects the participants’ daily activities and their ability to function at school and in other settings using special questionnaires designed for young people with migraine.

Participants will receive the medication to see how it affects the number of days they experience a migraine each month. During the study, the frequency, intensity, and duration of the headaches will be monitored. The researchers will also observe any adverse events, which are any side effects or unexpected health changes that occur during the treatment period.

Participants in the study will receive either rimegepant or a placebo. The medication is provided in an oral lyophilisate form, which is a substance designed to dissolve quickly in the mouth. During the study, participants will report on their experience with headache pain and other related symptoms to help researchers understand how the medication performs in different people.

The purpose of the study is to evaluate how well erenumab works compared with placebo in reducing the number of monthly migraine days in children and adolescents with chronic migraine. The study will also look at the safety of erenumab in this age group. The main focus is to see if there is a change in the number of migraine days per month from the start of the study to weeks 9 through 12 of the treatment period.

The study involves a treatment period where participants will be randomly assigned to receive either erenumab or placebo. During this time, participants will need to keep a daily electronic diary to record their headaches and migraine symptoms. The study will measure various aspects including the change in monthly migraine days, the change in monthly headache days, and whether participants achieve at least a 50 percent reduction in their monthly migraine days. The study will also assess how migraines affect daily activities and school performance in these young participants.

The study has a double-blind design, which means that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving placebo. Before starting treatment, participants will complete a baseline period where they record their headaches and migraines in an electronic diary. During this time, they must have at least 4 but fewer than 15 migraine days and fewer than 15 total headache days in a 28-day period. The main treatment phase lasts for 12 weeks, during which participants will receive injections of either erenumab or placebo. The maximum treatment period can extend up to 83 weeks, with the highest dose being 140 milligrams per injection.

Throughout the study, participants will continue to record their headaches and migraines in the electronic diary to track changes in the number of migraine days per month. The study will also measure changes in the number of total headache days, the severity of migraine attacks, and how much migraine affects daily activities and school performance. The main focus is on comparing the change in monthly migraine days between those receiving erenumab and those receiving placebo during weeks 9 through 12 of the treatment phase. Participants must have had a history of migraine with or without aura for at least 12 months before joining the study, and the diagnosis must follow established international headache classification criteria.

The study will test a medication called rimegepant sulfate (also known as PF-07899801), which belongs to a group of medicines called calcitonin gene-related peptide antagonists. This medicine comes as an orodispersible tablet that dissolves in the mouth and is taken by mouth. The purpose is to determine if rimegepant sulfate works better than placebo in preventing migraines in adolescents with chronic migraine.

The study will last several months and will have two parts. In the first part, participants will receive either rimegepant sulfate or placebo without knowing which one they are taking. After this initial phase, there will be an extended period where all participants will receive the active medication. Throughout the study, participants will need to keep track of their headache days and complete questionnaires about how migraines affect their daily activities.

Participants in the study will be given either cilostazol or a placebo to take orally. The main goal is to observe any differences in the occurrence of migraine-like attacks between those taking cilostazol and those taking the placebo. Additionally, the study will look at differences in heart rate and blood pressure, as well as any side effects that may occur during the study period. The study will help researchers understand the role of a substance in the body called cAMP, which is thought to be involved in migraines.

The trial will take place over a period of time, with participants being monitored for up to 12 hours after taking the medication. This will allow researchers to gather information on how cilostazol affects migraine symptoms and whether there are any differences between men and women in their response to the medication. The findings from this study could provide valuable insights into the treatment of migraines and help improve the understanding of how migraines work in the body.

The purpose of the study is to explore how eptinezumab works in the body and to identify potential markers that could predict how well patients respond to the treatment. Participants in the study will receive eptinezumab at a dose of 100 mg, and the effects will be observed over a period of 12 weeks. The study will look at changes in certain biological markers and how these changes relate to the effectiveness of the treatment. Some participants may receive a higher dose of 300 mg to compare the effects between different dosages.

Throughout the study, researchers will monitor various indicators in the body, such as levels of certain proteins and brain activity related to pain processing. These observations will help determine how eptinezumab affects the body and whether it can effectively reduce migraine symptoms. The study aims to provide valuable insights into the treatment of migraines and improve understanding of how eptinezumab can benefit patients suffering from this condition.

The purpose of the study is to explore how Rimegepant influences the body’s reaction to certain stimuli in both lean and obese individuals. Participants will receive a dose of Rimegepant and their body’s response to Capsaicin and other stimuli will be measured. The study will look at changes in blood flow in the skin and other body measurements, such as body weight and muscle mass, to understand how these factors might affect the medication’s impact.

The trial will take place over a short period, with participants receiving the medication and undergoing various assessments to monitor changes in their body’s responses. The study aims to provide insights into how Rimegepant works in people with different body compositions, which could help in understanding its potential benefits for treating migraine in individuals with obesity.

Participants in the study will be randomly assigned to receive either Atogepant or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 12 weeks, during which participants will take the assigned tablets daily. Throughout the study, researchers will monitor any side effects and changes in the frequency of migraine days. The goal is to see if Atogepant can reduce the number of migraine days and improve the quality of life for those taking it.

By the end of the study, researchers hope to gather enough information to determine if Atogepant is a safe and effective option for preventing migraines in young people. This could potentially lead to a new treatment option for those suffering from Chronic Migraine, helping them experience fewer headaches and improve their daily lives.

The purpose of the study is to assess how effective the combination of CGRP mAbs and onabotulinumtoxin A is compared to using CGRP mAbs alone. Participants will receive either the combination treatment or a treatment with CGRP mAbs and a placebo. The study will last for 12 weeks, during which the number of migraine days each participant experiences will be monitored. The goal is to see if the combination treatment can significantly reduce the frequency of migraines compared to the single treatment.

Participants in the study will receive their treatments through injections. Onabotulinumtoxin A will be administered as an intramuscular injection, which means it is injected directly into the muscle. The CGRP mAbs will be given as subcutaneous injections, meaning they are injected just under the skin. The study aims to provide valuable information on whether this dual therapy approach can offer better relief for those suffering from chronic migraines.

The purpose of the study is to observe changes in certain biochemical markers in the blood and saliva during a migraine attack and after treatment with Sumatriptan and Rimegepant. Participants will receive either Sumatriptan or Rimegepant during the trial, and their response to these treatments will be monitored. The study will help determine how these medications affect the levels of specific markers in the body, which could provide insights into their effectiveness in treating migraines.

Participants will be involved in a randomized cross-over trial, meaning they will receive both treatments at different times. The study will track the evolution of biochemical markers at four different points: before the migraine starts, at the beginning of the migraine, at the peak of the migraine, and two hours after treatment. This approach will help researchers understand the relationship between these markers and the response to migraine treatments.

Participants in the study will be randomly assigned to receive either Diclofenac Potassium, Rimegepant, or a placebo. Diclofenac Potassium is provided as an oral solution, while Rimegepant is given as an oral lyophilisate, which is a form that dissolves in the mouth. The study will observe the participants over a single migraine attack to see how quickly and effectively the medications relieve pain. The main goal is to determine the percentage of participants who become pain-free two hours after taking the medication, without needing any additional rescue medication.

Throughout the study, researchers will also monitor other factors such as the absence of the most bothersome symptom, changes in headache intensity, and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness of these treatments for people suffering from migraines, potentially offering new options for managing this condition.

Participants in the study will be randomly assigned to receive either Atogepant or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the main part of the study. This helps ensure that the results are not biased. The study will also include an “open-label extension,” where all participants may receive Atogepant after the initial phase, allowing researchers to gather more information about the medication’s long-term effects.

The main goal of the study is to evaluate how Atogepant, taken for seven consecutive days, affects the number of migraine days during the perimenstrual period, which is the time around the start of menstruation. The study will look at changes in the number of migraine days over three menstrual cycles. Participants will be monitored for any side effects and how well they tolerate the medication. The study is expected to continue until 2027, providing valuable insights into the potential benefits of Atogepant for those suffering from Menstrual Migraine.

Participants in the study will be asked to take either the hormone combination or vitamin E daily. The study will last for a total of 12 weeks, during which the number of migraine days will be monitored and recorded. This will help researchers understand if there is a significant change in the frequency of migraines when using these treatments. The study aims to provide insights into whether continuous daily use of these treatments can reduce the number of migraine days experienced by women with these specific types of migraines.

Throughout the study, participants will be monitored to assess the effectiveness of the treatments. The main focus will be on the change in the number of migraine days over a 28-day period, particularly during the last four weeks of the study. This information will help determine if either treatment is beneficial in managing migraines associated with menstrual cycles or the perimenopausal phase. The study will also look at other factors, such as the number of headache days and the number of migraine attacks, to provide a comprehensive understanding of the treatments’ effects.

The purpose of the study is to evaluate how effective Lu AG09222 is in preventing migraines in adults who have not found relief from previous preventive treatments. The study will involve participants with both episodic and chronic forms of migraine. During the trial, participants will be randomly assigned to different groups, and neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure that the results are unbiased.

Participants will be monitored over a period of time to track changes in their migraine frequency and severity. The study will also assess the safety of Lu AG09222 by checking for any side effects and changes in health indicators such as vital signs and laboratory test results. The trial aims to provide valuable information on whether this new treatment can offer a new option for people suffering from migraines.

The purpose of the study is to evaluate the effectiveness and safety of Rimegepant in preventing migraines. Participants will be randomly assigned to receive either Rimegepant or a placebo. The study will last for several weeks, during which participants will take the medication and report the number of migraine days they experience. The goal is to see if Rimegepant can significantly reduce the frequency of migraines compared to the placebo.

Throughout the study, participants will be monitored to ensure their safety and to gather information on how the treatment affects their quality of life. The study aims to provide valuable insights into whether Rimegepant can be an effective preventive treatment for migraines in young people, potentially offering a new option for managing this challenging condition.

Participants in the study will be randomly assigned to receive either Rimegepant or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The main goal is to see if Rimegepant can reduce the intensity of migraine pain within two hours after taking the medication. The study will also look at other factors, such as whether participants need additional medication within 24 hours and how the medication affects their ability to function normally during a migraine attack.

The trial will take place over a period of time, and participants will be monitored to assess the medication’s impact on their migraine symptoms. The study will help determine if Rimegepant is a suitable option for those who cannot use triptans, providing valuable information on its potential benefits and any side effects. The results will contribute to understanding how Rimegepant can be used in managing migraines effectively.

Participants in the study will be randomly assigned to receive either Rimegepant or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for several weeks, during which participants will take the medication every other day and report the number of migraine days they experience each month.

The main goal is to see if there is a reduction in the number of migraine days per month compared to before the study started. Additionally, the study will look at whether participants experience fewer days with moderate or severe headache pain and any changes in their ability to perform daily activities. The results will help determine if Rimegepant is an effective option for people who have not found relief with other migraine prevention treatments.

The study medication or placebo will be given as an infusion solution that is administered into a vein. The treatment period lasts for 12 weeks, during which participants will receive the study medication or placebo. The study uses a method called “double-blind,” which means neither the participants nor the doctors know who receives which treatment during the study.

Throughout the study, participants will need to keep track of their migraine days using an electronic diary. The researchers will monitor how the treatment affects migraine frequency and will also check for any changes in how often patients need to use other migraine medications. They will also evaluate how the treatment impacts the participants’ daily activities and overall quality of life.

Participants in the study will receive fremanezumab in the form of a solution for injection, either in a pre-filled pen or syringe. The study will last for a period of up to 36 months, during which participants will receive regular injections. Throughout the study, participants will be monitored for any side effects, including reactions at the injection site, and changes in their overall health, such as weight, height, and vital signs like blood pressure and heart rate. The study will also track the number of migraine days and the severity of headaches experienced by participants to assess the effectiveness of the treatment.

The goal of this trial is to gather information on the safety and effectiveness of fremanezumab in preventing migraines in young patients. By participating in this study, researchers hope to better understand how this medication can help reduce the frequency and severity of migraines in children and adolescents, ultimately improving their quality of life. The study will also look at any potential changes in the use of other headache medications and any impact on daily activities due to migraines.

Participants in the study will receive Fremanezumab injections once a month. The study will compare the effects of the treatment on patients with migraines, both with and without aura, which is a visual or sensory disturbance that can occur before a migraine. Researchers will use a technique called MR-Spectroscopy to measure changes in brain chemicals before and after the treatment period. This technique allows scientists to look at the levels of different substances in the brain without needing to perform surgery.

Throughout the study, changes in migraine frequency and intensity will be monitored using questionnaires. The study aims to understand if there is a link between the changes in brain chemicals and the symptoms experienced by patients. By the end of the study, researchers hope to gain insights into how Fremanezumab affects the brain and whether it can be an effective treatment for reducing the impact of migraines.

Participants in the study will receive either the MEDI0618 treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will receive multiple doses of the treatment. The researchers will monitor the participants to see how the treatment affects the frequency of their migraine headaches and to ensure the safety of the treatment.

The study aims to provide valuable information about the effectiveness and safety of MEDI0618 in preventing migraine headaches. By participating, individuals will contribute to research that could lead to better treatment options for people suffering from episodic migraines in the future.

The purpose of the study is to evaluate how well Atogepant works in treating a single migraine attack. Participants will be randomly assigned to receive either Atogepant or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the initial phase. This helps ensure that the results are not influenced by expectations about the treatment. After this phase, there will be an “open-label extension,” where all participants will have the opportunity to receive Atogepant.

Throughout the study, participants will take the medication when they experience a migraine attack and will be monitored for their response to the treatment. The study will assess various outcomes, such as the relief of headache pain and the ability to return to normal activities. The trial aims to provide valuable information about the safety and effectiveness of Atogepant for people who suffer from migraines.

Participants in the study will be randomly assigned to receive either lasmiditan or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will last up to 20 weeks and may involve up to four visits. During this time, researchers will monitor the participants to see how well the treatment works and if there are any side effects.

The main goal of the study is to see if lasmiditan can provide pain relief for children experiencing migraines. This research is important because it could lead to new treatment options for young people who suffer from these debilitating headaches. The study is conducted in a way that ensures the safety and well-being of all participants throughout the trial period.

The purpose of this research is to determine if eptinezumab, when combined with basic education about headaches, can help prevent migraines and treat medication overuse headaches. During the study, participants will receive either eptinezumab or placebo as an addition to educational information about headache management. The medication or placebo will be given through an infusion into a vein.

The study will last for 72 weeks, during which participants may receive up to 300 milligrams of the study medication. Throughout the study, participants will need to keep track of their headaches and medication use in an electronic diary. The researchers will monitor how the treatment affects both the frequency of migraines and the overuse of headache medications.

The purpose of this study is to evaluate how well eptinezumab can prevent migraines in people who experience them frequently. Participants in the study will be randomly assigned to receive either eptinezumab or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased and reliable.

Throughout the study, participants will receive regular infusions and will be monitored for changes in the number of migraine days they experience each month. The study will last for several months, allowing researchers to gather enough information to determine the effectiveness of eptinezumab in reducing the frequency of migraines. Participants will also be observed for any side effects or safety concerns related to the treatment. The ultimate goal is to find a reliable preventive treatment for those suffering from chronic migraine.

The purpose of the study is to evaluate how safe and well-tolerated rimegepant is when used for the acute treatment of migraines in young people. Participants in the study will take the medication over a period of time, and researchers will monitor them for any side effects or adverse reactions. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered.

Throughout the study, participants will be regularly assessed to ensure their safety and to gather information on any side effects they may experience. The study aims to provide valuable insights into the use of rimegepant for managing migraines in children and adolescents, helping to determine its suitability as a treatment option for this age group.

The purpose of the study is to evaluate how well rimegepant works in treating acute migraine attacks, which can occur with or without aura. Aura refers to visual or sensory disturbances that some people experience before a migraine headache. Participants in the study will receive either rimegepant or a placebo and will be monitored to see if they experience pain relief and freedom from other bothersome symptoms like nausea, sensitivity to light (photophobia), and sensitivity to sound (phonophobia) within two hours of taking the medication.

The study will take place over a period of time, during which participants will be asked to report their symptoms and any changes they experience. The goal is to determine if rimegepant can help reduce the severity and duration of migraine attacks in young people, allowing them to return to their normal activities more quickly. The study will also assess whether participants need additional medication to manage their symptoms after taking the study medication.

The purpose of the study is to determine how effective this treatment is for people with chronic migraine who have not responded well to other treatments. Participants in the study will receive either the Botox treatment or a placebo. The study will monitor changes in the number of headache days and the intensity of headaches over a period of time. Participants will be observed for any side effects or adverse events that may occur during the study.

The study will take place over several weeks, with regular check-ins to assess the impact of the treatment. Participants will be asked to maintain their current headache medication routines throughout the study. The goal is to see if the Botox treatment can reduce the frequency and severity of headaches and improve the quality of life for those suffering from chronic migraine.

Participants in the study will be randomly assigned to receive either Atogepant, Topiramate, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drugs. The study will last for several weeks, during which participants will take the assigned medication and report any side effects or changes in their migraine symptoms. The study aims to find out if Atogepant is as effective and safe as Topiramate, which is already used for migraine prevention.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their migraine patterns. The study will also include an open-label extension, where all participants may have the opportunity to receive Atogepant to further assess its long-term safety and effectiveness. This trial is an important step in understanding how these medications can help people who suffer from migraines and improve their quality of life.

Participants in the study will receive either Galcanezumab or a placebo. The study will monitor changes in the number of migraine headache days over a period of three months. The goal is to see if there is a reduction in the frequency of migraines for those receiving the treatment compared to those receiving the placebo.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased and reliable. The trial is expected to continue until 2026, providing valuable information on the effectiveness of Galcanezumab in managing Chronic Migraine in adolescents.

Participants in the study will receive either Galcanezumab or a placebo over a period of three months. The study is designed to compare the effects of Galcanezumab with the placebo to see if it can reduce the number of days participants experience migraine headaches each month. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, which is known as a double-blind study.

The main goal is to determine if Galcanezumab is better than the placebo in decreasing the frequency of migraine headaches. This study is part of ongoing research to find effective treatments for managing migraines in young people, aiming to improve their quality of life by reducing the burden of migraine attacks.